BioMarin Withdraws Roctavian

This announcement appears in BioMarin’s 2025 full-year financial report: “Following the company’s October announcement to explore options to divest ROCTAVIAN, BioMarin undertook a comprehensive effort to identify a potential buyer. Despite these efforts, BioMarin was unable to identify a qualified buyer and has decided to withdraw ROCTAVIAN from the market voluntarily.” There are no FVIII […]

Comments (0)

Bleeding Disorders

Mar 9 2026

george

Diagnostic Equity Case: Prolonged PTT

This question was posted on the Diagnostic Equity website on March 5, 2026: “My PT is normal at 12 seconds, but my PTT (aPTT, APTT) is elevated at 72 seconds. I had excessive bleeding after a dental procedure. My hematologist said a mixing study was done and it was corrected, so what does a mixing […]

Blog

Xarelto Sales Decline

Bayer said Wednesday 3-4-26 that it expects the erosion of Xarelto sales to “slightly accelerate” this year as the oral anticoagulant faces further competition from generics. Revenue from the product is forecast to fall by between 35% and 40% in 2026, compared to a roughly 33% decline last year to €2.3 billion ($2.7 billion). The company […]

Comments (1)

Anticoagulant Therapy

Mar 4 2026

george

Research Report Examines Efficacy of Chemiluminescence HIT Assay

Here is an open-access article describing the efficacy of a chemiluminescence HIT assay: Bowyer A, Kohama K, Patel I, et al’A new, rapid, chemiluminescence enzyme assay for the detection of heparin-induced thrombocytopenia: a comparison between functional and immune heparin-induced thrombocytopenia assays, Res Prac in Thrombosis and Haemostasis,2026;10, 103373, ISSN 2475-0379, https://doi.org/10.1016/j.rpth.2026.103373. Abstract Background Heparin-induced thrombocytopenia […]

Thrombophilia

Review: AI in Thrombosis and Hemostasis

Click here for this open-access article that describes AI in thrombosis and hemostasis. (This is the first time we’ve posted about AI). Altememi MA, Favaloro EJ, Islam MZ, Santhakumar AB. Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions. Clin Chem Lab Med. […]

Comments (0)

Global Hemostasis Assays

Mar 2 2026

george

Bleeding and Thrombosis in Chronic Kidney Disease

Click this open-access article on the adverse outcomes of anticoagulation in chronic kidney disease: Jones A, Swan D, Lisman T, Barnes GD, Thachil J. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost. 2024;22:323–36. doi: 10.1016/j.jtha.2023.09.020. PMID: 37778512. Abstract Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often […]

Comments (0)

Anticoagulant Therapy

Mar 2 2026

george

Emicizumab Dosage

Here is an open-access article on current emicizumab dosage: van der Zwet K, de Vos ADW, Cnossen MH, et al; OPTI-CLOT Study Group and SYMPHONY Consortium. Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study. J Thromb Haemost. 2026;24:890–99. doi: 10.1016/j.jtha.2025.10.029. PMID: 41207564. Abstract Background Emicizumab provides effective prophylaxis […]

Bleeding Disorders

March. 2026 Cheat Sheet

Click March 2026 Cheat Sheet for your Fritsma Factor monthly Cheat Sheet that summarizes our February posts and those before. If you’d like a push copy of the Cheat Sheet, updated with links to last month’s posts, complete the brief form at the right. The Cheat Sheet, Quick Questions, posts, informative PowerPoint modules, and more […]

Cheat Sheets

March 2026 QQ: LAC Testing When the Patient is on DOAC

Our March 2026 Quick Question is a poll that asks, “How do you test for LAC when the patient is on a DOAC?” This question arises from the discussion in our 2-19-26 post, “CAP Today: Hemostasis Testing While on DOACs.” Often, the provider requests LAC testing for a thrombosis patient on anticoagulation. While the anticoagulant […]

Comments (0)

Anticoagulant Therapy

Feb 27 2026

george

February 2026 QQ Results: DOAC Names

Our February 2026 Quick Question was a quiz that drew 42 responses. The stem asked, “Which DOAC is a direct thrombin inhibitor?” Your answers: Apixaban: 9 (21%) Betrixaban: 0 Dabigatran: 32 (76%) Edoxaban: 0 Rivaroxaban: 1 (3%) We performed well on this question. No one chose betrixaban, an FXa-directed oral anticoagulant that was withdrawn in […]

Comments (1)

Anticoagulant Therapy

All Posts

BioMarin Withdraws Roctavian

Diagnostic Equity Case: Prolonged PTT

Xarelto Sales Decline

Research Report Examines Efficacy of Chemiluminescence HIT Assay

Review: AI in Thrombosis and Hemostasis

Bleeding and Thrombosis in Chronic Kidney Disease

Emicizumab Dosage

March. 2026 Cheat Sheet

March 2026 QQ: LAC Testing When the Patient is on DOAC

February 2026 QQ Results: DOAC Names

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question